Yasmin - Drug Monograph

Introduction

Yasmin is a combined oral contraceptive (COC) containing drospirenone, a progestin with antimineralocorticoid and antiandrogenic activity, paired with ethinyl estradiol. It is widely prescribed for the prevention of pregnancy and is also used off-label for conditions benefiting from antiandrogenic effects, such as acne and premenstrual dysphoric disorder. Its formulation distinguishes it from older COCs by virtue of drospirenone's pharmacologic profile, which resembles endogenous progesterone more closely than earlier progestins.

Drug Class and Overview

• Drug class: Combination hormonal contraceptive (estrogen + progestin).
• Related agents: Other combined oral contraceptives (e.g., levonorgestrel-, norethindrone-, desogestrel-, norgestimate-containing products); other drospirenone-containing COCs (e.g., Yaz, Beyaz); progestin-only contraceptives.
• Distinguishing features: Drospirenone is a spironolactone analog with antimineralocorticoid activity (may reduce fluid retention) and antiandrogenic activity (may benefit acne and hirsutism), while lacking significant androgenic activity seen with older progestins.

Mechanism of Action

Combined oral contraceptives primarily prevent pregnancy through three coordinated mechanisms:

1. Suppression of ovulation via inhibition of the hypothalamic-pituitary-ovarian axis; ethinyl estradiol and drospirenone suppress the mid-cycle luteinizing hormone (LH) surge and dampen follicle-stimulating hormone (FSH) release.
2. Thickening of cervical mucus, reducing sperm penetration into the upper genital tract.
3. Endometrial alterations, producing a less receptive environment for implantation.

Drospirenone binds the progesterone receptor with high affinity and, unlike many progestins, also antagonizes the mineralocorticoid receptor (reducing sodium/water retention) and the androgen receptor (reducing sebum production and androgenic effects).

Indications

• Prevention of pregnancy (FDA-approved).
• Premenstrual dysphoric disorder (PMDD) (Yaz formulation carries this indication; Yasmin is used off-label for similar benefit).
• Moderate acne vulgaris in females ≥14 years old who desire contraception (Yaz has this indication; Yasmin is sometimes used off-label given shared drospirenone content).
• Note: Any off-label use should be evidence-based and individualized.

Dosage and Administration

• Adult dosing (≥18 years): One tablet daily for 21 consecutive days, followed by 7 days of inactive tablets (28-day cycle). Each active tablet contains ethinyl estradiol 0.03 mg and drospirenone 3 mg.
• Administration tips: Take at the same time daily; tablets may be taken with food or water to reduce nausea.
• Initiation timing:
• First-day start: Begin on the first day of menses (immediate protection).
• Sunday start: Begin on the first Sunday after menses begins; backup contraception recommended for 7 days unless initiated as a first-day start.
• Missed doses: Standard CDC and ACOG guidance applies; refer to product labeling for step-by-step instructions. Two or more missed active tablets typically require 7 days of backup contraception.
• Renal impairment: Not recommended in severe renal impairment (CrCl <30 mL/min) due to drospirenone's potential to cause hyperkalemia via antimineralocorticoid activity.
• Hepatic impairment: Contraindicated in severe hepatic disease; use cautiously in mild-to-moderate impairment.
• Pediatric: Generally not indicated before menarche; safety and efficacy established for postmenarchal adolescents.
• Geriatric: Not indicated; combined hormonal contraceptives are not recommended for postmenopausal women.
• Pregnancy: Contraindicated; discontinue if pregnancy occurs.

Pharmacokinetics

• Absorption: Ethinyl estradiol and drospirenone are well absorbed orally. Drospirenone's bioavailability is approximately 76%; ethinyl estradiol undergoes first-pass metabolism with bioavailability around 40–45%.
• Distribution: Both agents are highly protein-bound to plasma proteins (ethinyl estradiol to albumin; drospirenone to albumin without binding to sex hormone-binding globulin [SHBG] in a clinically relevant manner). Drospirenone does not displace testosterone from SHBG.
• Metabolism:
• Ethinyl estradiol: Hepatic metabolism via cytochrome P450 (primarily CYP3A4), undergoing conjugation (glucuronide and sulfate).
• Drospirenone: Independent of CYP450 to a significant degree; metabolized by reduction, sulfation, and oxidation pathways; minimal CYP3A4 involvement.
• Elimination: Both are excreted in feces and urine as metabolites.
• Half-life: Drospirenone ~30 hours; ethinyl estradiol ~24 hours.

Contraindications

• Thrombotic/thromboembolic disorders (deep vein thrombosis, pulmonary embolism) — current or history.
• Cerebrovascular or coronary artery disease (current or history).
• Migraine with aura (due to elevated ischemic stroke risk).
• Severe hepatic disease or hepatic dysfunction.
• Known or suspected pregnancy.
• Known or suspected hormone-sensitive malignancy (e.g., breast cancer).
• Undiagnosed abnormal uterine bleeding.
• Severe renal impairment or acute renal failure.
• Adrenal insufficiency (relative caution given antimineralocorticoid activity).
• Hypersensitivity to any component.
• Concomitant use with drugs that raise potassium substantially (e.g., potassium-sparing diuretics, ACE inhibitors, ARBs, heparin) — relative; requires potassium monitoring.

Warnings and Precautions

• Venous thromboembolism (VTE) risk: COCs increase VTE risk compared with non-use; risk is elevated in the first year of use and after prolonged immobility, surgery, or obesity. Drospirenone-containing COCs have been the subject of post-marketing debate regarding VTE risk relative to levonorgestrel-containing products; current labeling reflects that drospirenone products may carry a modestly higher VTE risk.
• Arterial thromboembolism: Risk of stroke and myocardial infarction, particularly in women with hypertension, hyperlipidemia, diabetes, obesity, smokers, and migraine with aura.
• Hyperkalemia: Possible with drospirenone due to antimineralocorticoid effects, especially in renal impairment or with potassium-elevating drugs; consider monitoring potassium in at-risk patients during the first treatment cycle.
• Hypertension: May increase blood pressure; contraindicated in uncontrolled hypertension.
• Hepatic tumors: Rare association with benign hepatic adenomas and hepatocellular carcinoma with prolonged COC use.
• Glucose tolerance: COCs may impair glucose tolerance; monitor diabetic patients.
• Lipid effects: Estrogen may increase triglycerides; caution with severe hypertriglyceridemia.
• Mood changes: Monitor for depression or worsening PMDD symptoms.
• Smoking: Strongly discouraged in COC users ≥35 years old due to cardiovascular risk.
• Reduced efficacy: With missed doses, vomiting/diarrhea, drug interactions (e.g., hepatic enzyme inducers).

Drug Interactions

• CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, primidone, topiramate, St. John's wort): Reduce efficacy; use backup contraception or non-hormonal method.
• Antibiotics (e.g., rifampin): Reduce efficacy; use backup contraception.
• Antiretroviral therapy: Some protease inhibitors and non-nucleoside reverse transcriptase inhibitors can alter levels; consult HIV-specific guidance.
• Potassium-elevating drugs (ACE inhibitors, ARBs, potassium-sparing diuretics, aldosterone antagonists, heparin, NSAIDs in some settings): Monitor potassium, especially in renal impairment.
• Thyroid hormone replacement: May increase thyroxine-binding globulin; adjust thyroid dosing if needed.
• Smoking: Synergistic cardiovascular risk — discourage use, especially in women ≥35 years.

Adverse Effects

Common: Nausea, breast tenderness, headache, breakthrough bleeding/spotting, mood changes, mild fluid retention, dysmenorrhea. Less common: Acne improvement (often), melasma, weight changes, decreased libido, vaginal discharge changes. Serious (rare): Venous thromboembolism, pulmonary embolism, stroke, myocardial infarction, hepatic adenoma, severe hyperkalemia (in at-risk patients), gallbladder disease, hypertension, cholestatic jaundice, hypersensitivity reactions. Frequency note: Quantitative frequencies vary by source; counseling should focus on early warning symptoms of thrombosis (leg swelling/pain, chest pain, shortness of breath, sudden severe headache, visual changes) and hepatic dysfunction (jaundice, dark urine).

Monitoring Parameters

• Blood pressure: Before initiation and periodically during use.
• Body mass index (BMI), lipid panel, glucose: As clinically indicated based on risk factors.
• Potassium: If renal impairment, on potassium-elevating drugs, or on other risk factors for hyperkalemia — measure at baseline and during first cycle.
• Breast and pelvic examination: Per general preventive care guidelines.
• Cervical cancer screening (Pap/HPV): Per current guidelines regardless of COC use.
• Smoking status and migraine-with-aura history: Reassess at each visit.
• Adherence and side effects: Discuss at follow-up (e.g., 3-month check-in for new starts).

Patient Education

• Take one tablet daily at the same time; missed pills require backup contraception.
• Use barrier protection (condoms) to prevent sexually transmitted infections.
• Report warning signs immediately: leg pain/swelling, chest pain, shortness of breath, sudden severe headache, vision changes, jaundice, severe abdominal pain.
• Smoking and combined hormonal contraceptives together — especially after age 35 — significantly increase cardiovascular risk.
• Tell clinicians about all medications, including herbal products (e.g., St. John's wort) and over-the-counter drugs.
• Vomiting or severe diarrhea can reduce effectiveness; use backup contraception if these occur.
• Anticipate breakthrough bleeding, especially in the first few cycles; report persistent bleeding.
• Yasmin does not protect against HIV or other sexually transmitted infections.

Clinical Pearls

• Drospirenone's antimineralocorticoid activity can cause hyperkalemia — relevant in patients with renal disease or on ACE inhibitors/ARBs/spironolactone/potassium-sparing diuretics.
• COCs are contraindicated with migraine with aura due to markedly increased stroke risk; progestin-only or non-hormonal methods are safer alternatives.
• All COCs increase VTE risk, but absolute risk remains low in reproductive-age women; counsel on signs of VTE and modifiable risk factors (smoking, immobilization, obesity).
• Drospirenone's antiandrogenic profile can be beneficial in women with acne or hirsutism, but is not a primary therapy for these unless contraception is also desired.
• Anticonvulsants and rifampin are classic CYP3A4 inducers that significantly reduce COC efficacy — counsel about backup contraception or alternative methods.
• Smoking in women ≥35 years is generally a discontinuation trigger for combined hormonal contraceptives due to cardiovascular risk.

References

1. Bayer HealthCare Pharmaceuticals. Yasmin (drospirenone and ethinyl estradiol) Prescribing Information. U.S. Food and Drug Administration.
2. Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.
3. American College of Obstetricians and Gynecologists. Combined Hormonal Contraceptives Practice Bulletin.
4. Goodman & Gilman's The Pharmacological Basis of Therapeutics.
5. Katzung BG. Basic & Clinical Pharmacology.
6. Lexicomp Online. Drospirenone/Ethinyl Estradiol (Yasmin) — Clinical Pharmacology.
7. World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 5th edition.
8. Practice Committee of the American Society for Reproductive Medicine. Hormonal Contraception and Cardiovascular Risk.
9. American Academy of Dermatology. Guidelines of Care for the Management of Acne Vulgaris.
10. Stachenfeld NS, Taylor HS. Effects of estrogen and progesterone on the cardiovascular system. New England Journal of Medicine (general review articles).